NewsAI-assisted

Leadership Excellence: Organon Welcomes Oh So-yun

Oh So-yun named Country Lead for Organon Malaysia, leveraging 26 years of pharmaceutical leadership.

Priyanka Patil
By Priyanka Patil
Marketing Associate · Pharma Now
Dec 23, 2024Updated Jun 26, 2025 · 2 min read
Share
Leadership Excellence: Organon Welcomes Oh So-yun
https://www.koreabiomed.com/news/articleView.html?idxno=26104
AI-assisted reporting
Reviewed by Priyanka Patil, Marketing Associate · Pharma Now

Organon Korea announced that Oh So-yun, its Sales and Customers Lead, will assume the role of Country Lead for Organon Malaysia effective January 1, 2025.

Leadership and Achievements

With over 26 years in the pharmaceutical industry, Oh has significantly contributed to Organon Korea’s success since its establishment. As head of the sales division, she spearheaded growth initiatives in chronic disease management and women’s health, positioning the company as a leader in these areas.

Oh has successfully managed key products like Atozet, Propecia, Singulair, Vytorin, and Cozaar, implementing strategies to enhance profitability and diversify the portfolio. Her leadership of a sales team of more than 150 members has been widely acknowledged for driving organizational development.

New Role in Malaysia

In her new position, Oh will leverage her vast experience and leadership skills to collaborate with the Malaysian team and advance Organon’s mission and growth in the region.

Previous Roles

Before joining Organon Korea, Oh held leadership roles at MSD Korea, including Division Director for Primary Care (focusing on chronic diseases) and Diversified Brands (spanning respiratory, dermatology, and urology therapeutic areas).

Organon anticipates that Oh’s expertise will bring continued success to the company’s operations in Malaysia.

TopicsNews
Priyanka Patil
Written by
Priyanka Patil
Marketing Associate · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →